Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
βIV-Spectrin/STAT3 complex regulates fibroblast phenotype, fibrosis, and cardiac function
Nehal J. Patel, Drew M. Nassal, Amara D. Greer-Short, Sathya D. Unudurthi, Benjamin W. Scandling, Daniel Gratz, Xianyao Xu, Anuradha Kalyanasundaram, Vadim V. Fedorov, Federica Accornero, Peter J. Mohler, Keith J. Gooch, Thomas J. Hund
Nehal J. Patel, Drew M. Nassal, Amara D. Greer-Short, Sathya D. Unudurthi, Benjamin W. Scandling, Daniel Gratz, Xianyao Xu, Anuradha Kalyanasundaram, Vadim V. Fedorov, Federica Accornero, Peter J. Mohler, Keith J. Gooch, Thomas J. Hund
View: Text | PDF
Research Article Cardiology Cell biology

βIV-Spectrin/STAT3 complex regulates fibroblast phenotype, fibrosis, and cardiac function

  • Text
  • PDF
Abstract

Increased fibrosis is a characteristic remodeling response to biomechanical and neurohumoral stress and a determinant of cardiac mechanical and electrical dysfunction in disease. Stress-induced activation of cardiac fibroblasts (CFs) is a critical step in the fibrotic response, although the precise sequence of events underlying activation of these critical cells in vivo remain unclear. Here, we tested the hypothesis that a βIV-spectrin/STAT3 complex is essential for maintenance of a quiescent phenotype (basal nonactivated state) in CFs. We reported increased fibrosis, decreased cardiac function, and electrical impulse conduction defects in genetic and acquired mouse models of βIV-spectrin deficiency. Loss of βIV-spectrin function promoted STAT3 nuclear accumulation and transcriptional activity, and it altered gene expression and CF activation. Furthermore, we demonstrate that a quiescent phenotype may be restored in βIV-spectrin–deficient fibroblasts by expressing a βIV-spectrin fragment including the STAT3-binding domain or through pharmacological STAT3 inhibition. We found that in vivo STAT3 inhibition abrogates fibrosis and cardiac dysfunction in the setting of global βIV-spectrin deficiency. Finally, we demonstrate that fibroblast-specific deletion of βIV-spectrin is sufficient to induce fibrosis and decreased cardiac function. We propose that the βIV-spectrin/STAT3 complex is a determinant of fibroblast phenotype and fibrosis, with implications for remodeling response in cardiovascular disease (CVD).

Authors

Nehal J. Patel, Drew M. Nassal, Amara D. Greer-Short, Sathya D. Unudurthi, Benjamin W. Scandling, Daniel Gratz, Xianyao Xu, Anuradha Kalyanasundaram, Vadim V. Fedorov, Federica Accornero, Peter J. Mohler, Keith J. Gooch, Thomas J. Hund

×

Figure 5

Rescue of quiescent fibroblast phenotype in βIV-spectrin–deficient fibroblasts.

Options: View larger image (or click on image) Download as PowerPoint
Rescue of quiescent fibroblast phenotype in βIV-spectrin–deficient fibro...
(A) Representative confocal microscopy images (original magnification, ×40) of permeabilized adult qv4J cardiac fibroblasts (CFs) immunostained for βIV-spectrin (red), STAT3 (green), and DAPI (blue in merged image) following transfection of empty vector plasmid (control) or βIV,10-C rescue construct (scale bar: 5 μm). (B) Summary data (mean ± SEM) of STAT3 nuclear localization in WT and qv4J CFs transfected with empty vector or βIV,10-C. *P < 0.05 by 1-way ANOVA with Holm-Sidak post hoc pairwise comparison; n = 5 per group where N is the number of independent preparations (5 cells analyzed per preparation). (C and D) Summary data (mean ± SEM) of BrdU intensity measured at 6 and 12 hours following BrdU treatment in WT and qv4J CFs either (C) transfected with empty vector or βIV,10-C, or (D) treated with STAT3 inhibitor S3I-201 (100 μM) or vehicle (3% DMSO in PBS). n = 6 independent preparations for each group; data normalized to WT control (empty vector or vehicle) at 12 hours; *P < 0.05 by 1-way ANOVA with Holm-Sidak post hoc pairwise comparison.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts